Literature DB >> 20829454

Tau reduction prevents Abeta-induced defects in axonal transport.

Keith A Vossel1, Kai Zhang, Jens Brodbeck, Aaron C Daub, Punita Sharma, Steven Finkbeiner, Bianxiao Cui, Lennart Mucke.   

Abstract

Amyloid-β (Aβ) peptides, derived from the amyloid precursor protein, and the microtubule-associated protein tau are key pathogenic factors in Alzheimer's disease (AD). How exactly they impair cognitive functions is unknown. We assessed the effects of Aβ and tau on axonal transport of mitochondria and the neurotrophin receptor TrkA, cargoes that are critical for neuronal function and survival and whose distributions are altered in AD. Aβ oligomers rapidly inhibited axonal transport of these cargoes in wild-type neurons. Lowering tau levels prevented these defects without affecting baseline axonal transport. Thus, Aβ requires tau to impair axonal transport, and tau reduction protects against Aβ-induced axonal transport defects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20829454      PMCID: PMC3024010          DOI: 10.1126/science.1194653

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  12 in total

1.  Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons.

Authors:  Helena Decker; Karen Y Lo; Sandra M Unger; Sergio T Ferreira; Michael A Silverman
Journal:  J Neurosci       Date:  2010-07-07       Impact factor: 6.167

2.  Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice.

Authors:  Aidong Yuan; Asok Kumar; Corrinne Peterhoff; Karen Duff; Ralph A Nixon
Journal:  J Neurosci       Date:  2008-02-13       Impact factor: 6.167

3.  Differential regulation of dynein and kinesin motor proteins by tau.

Authors:  Ram Dixit; Jennifer L Ross; Yale E Goldman; Erika L F Holzbaur
Journal:  Science       Date:  2008-01-17       Impact factor: 47.728

4.  Mitochondrial abnormalities in Alzheimer's disease.

Authors:  K Hirai; G Aliev; A Nunomura; H Fujioka; R L Russell; C S Atwood; A B Johnson; Y Kress; H V Vinters; M Tabaton; S Shimohama; A D Cash; S L Siedlak; P L Harris; P K Jones; R B Petersen; G Perry; M A Smith
Journal:  J Neurosci       Date:  2001-05-01       Impact factor: 6.167

5.  Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons.

Authors:  Yanfang Rui; Priyanka Tiwari; Zuoping Xie; James Q Zheng
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

6.  Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.

Authors:  Erik D Roberson; Kimberly Scearce-Levie; Jorge J Palop; Fengrong Yan; Irene H Cheng; Tiffany Wu; Hilary Gerstein; Gui-Qiu Yu; Lennart Mucke
Journal:  Science       Date:  2007-05-04       Impact factor: 47.728

7.  Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta.

Authors:  G Pigino; G Morfini; Y Atagi; A Deshpande; C Yu; L Jungbauer; M LaDu; J Busciglio; S Brady
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

8.  Glutamate and amyloid beta-protein rapidly inhibit fast axonal transport in cultured rat hippocampal neurons by different mechanisms.

Authors:  Hiromi Hiruma; Takashi Katakura; Sanae Takahashi; Takafumi Ichikawa; Tadashi Kawakami
Journal:  J Neurosci       Date:  2003-10-01       Impact factor: 6.167

9.  Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease.

Authors:  A Ebneth; R Godemann; K Stamer; S Illenberger; B Trinczek; E Mandelkow
Journal:  J Cell Biol       Date:  1998-11-02       Impact factor: 10.539

Review 10.  Neurotrophic factors in Alzheimer's disease: role of axonal transport.

Authors:  K Schindowski; K Belarbi; L Buée
Journal:  Genes Brain Behav       Date:  2008-02       Impact factor: 3.449

View more
  235 in total

1.  Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.

Authors:  Sophie Sokolow; Kristen M Henkins; Tina Bilousova; Bianca Gonzalez; Harry V Vinters; Carol A Miller; Lindsey Cornwell; Wayne W Poon; Karen H Gylys
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

2.  Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.

Authors:  Donna M Barten; Patrizia Fanara; Cathy Andorfer; Nina Hoque; P Y Anne Wong; Kristofor H Husted; Gregory W Cadelina; Lynn B Decarr; Ling Yang; Victoria Liu; Chancy Fessler; Joan Protassio; Timothy Riff; Holly Turner; Christopher G Janus; Sethu Sankaranarayanan; Craig Polson; Jere E Meredith; Gemma Gray; Amanda Hanna; Richard E Olson; Soong-Hoon Kim; Gregory D Vite; Francis Y Lee; Charles F Albright
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

3.  Early and selective impairments in axonal transport kinetics of synaptic cargoes induced by soluble amyloid β-protein oligomers.

Authors:  Yong Tang; David A Scott; Utpal Das; Steven D Edland; Kryslaine Radomski; Edward H Koo; Subhojit Roy
Journal:  Traffic       Date:  2012-02-27       Impact factor: 6.215

4.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration.

Authors:  Tomasz Jaworski; Benoit Lechat; David Demedts; Lies Gielis; Herman Devijver; Peter Borghgraef; Hans Duimel; Fons Verheyen; Sebastian Kügler; Fred Van Leuven
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

Review 5.  Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.

Authors:  Nicholas M Kanaan; Gustavo F Pigino; Scott T Brady; Orly Lazarov; Lester I Binder; Gerardo A Morfini
Journal:  Exp Neurol       Date:  2012-06-19       Impact factor: 5.330

Review 6.  Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease.

Authors:  Yanina Ivashko Pachima; Liu-yao Zhou; Peng Lei; Illana Gozes
Journal:  J Mol Neurosci       Date:  2016-02       Impact factor: 3.444

7.  Loss of the m-AAA protease subunit AFG₃L₂ causes mitochondrial transport defects and tau hyperphosphorylation.

Authors:  Arun Kumar Kondadi; Shuaiyu Wang; Sara Montagner; Nikolay Kladt; Anne Korwitz; Paola Martinelli; David Herholz; Michael J Baker; Astrid C Schauss; Thomas Langer; Elena I Rugarli
Journal:  EMBO J       Date:  2014-03-28       Impact factor: 11.598

Review 8.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

9.  Age and Alzheimer's pathology disrupt default mode network functioning via alterations in white matter microstructure but not hyperintensities.

Authors:  Christopher A Brown; Yang Jiang; Charles D Smith; Brian T Gold
Journal:  Cortex       Date:  2018-04-19       Impact factor: 4.027

Review 10.  Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders.

Authors:  Jerel Adam Fields; Wilmar Dumaop; Leslie Crews; Anthony Adame; Brian Spencer; Jeff Metcalf; Johnny He; Edward Rockenstein; Eliezer Masliah
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.